Investing


Emile Wamsteker | Bloomberg | Getty Images

Pedestrians walk across the street from a Merck & Co. facility in Summit, New Jersey

Incyte said on Friday an independent committee concluded that its drug for a type of skin cancer in combination with Merck‘s Keytruda failed to meet the main goal in a late-stage study.

Incyte shares fell 20 percent in premarket trading Friday, while Merck shares were down about 2 percent.

The two companies would stop the study as it did not meet the primary goal of improving progression-free survival compared to patients on Keytruda monotherapy.

Merck’s Keytruda is approved for the treating several forms of cancer, including lung cancer and advanced melanoma. The companies said the study’s second main goal of overall survival was also not expected to reach a statistical significance.

The study was evaluating a combination of Incyte’s inhibitor Epacadostat and Merck’s Keytruda for the treatment of metastatic melanoma.



Source link

Products You May Like

Articles You May Like

General Electric earnings Q1 2018
1MDB is financially healthy, says CEO Arul Kanda Kandasamy
New-car shoppers face higher costs from auto prices, loan rates
Zuckerberg should look to Starbucks CEO on how to handle a crisis
Tax cut windfall has gone more to executives than to workers: TrimTabs

Leave a Reply

Your email address will not be published. Required fields are marked *